Savara develops new therapies for rare respiratory diseases, MOLBREEVI expected to address significant market.

viernes, 9 de enero de 2026, 8:02 am ET1 min de lectura
SVRA--

Savara Inc. is developing new therapies for rare respiratory diseases, with a focus on MOLBREEVI. The company cautions that statements regarding potential health benefits, regulatory submissions, and market size are forward-looking and subject to change.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios